Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa randomized, double-blind, placebo-controlled dose-ranging study of inhaled AZD1402 in adults with asthma
2020-002828-37Phase 2Terminated
- Sponsor
- AstraZeneca
- Start
- May 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in asthma comparing AZD1402 with Placebo (2 arms). Primary endpoint: Safety and tolerability of AZD1402 (Part 1). Started May 2021; status: terminated.
02
Drugs
elarekibep
03
Conditions
asthma
Beyond the preview
Go deeper on 2020-002828-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002828-37.